Interestingly, p-mTOR (Ser2448), a marker of mTOR pathway activity, is expressed at a low average level in MPM compared with other cancers (Fig. S1A), whereas p-RICTOR (Thr1135), an mTORC2 inhibitor and part of a feedback mechanism that negatively regulates AKT/mTORC1, is expressed at the second highest level in the pan-cancer cohort, just after sarcoma (SARC) (Fig. S1B). Here, RICTOR is linked to sarcoma.